Keyphrases
Angiogenesis
8%
Angiogenic Growth Factors
25%
Angiogenic Therapy
8%
Basic Fibroblast Growth Factor (bFGF)
16%
Bidirectional Association
8%
Cavernosal Smooth muscle
8%
Cell Interaction
8%
Corporal
58%
Corpus Cavernosum
16%
Diet-induced
16%
Endothelial Cells
16%
Endothelium
8%
Erectile Dysfunction
100%
Erectile Function
16%
Functional Benefit
16%
Growth Factor Receptor Signaling
8%
Health Problems
8%
Healthcare
8%
Hypercholesterolemia
75%
Individual Cells
8%
Initial Funding
8%
Ligand-mediated
8%
Ligand-receptor Binding
16%
Nerve
8%
Nitric Oxide
16%
Non-traumatic
16%
Number of Patients
8%
Pathophysiology
8%
Penile Tissue
16%
Phosphodiesterase Type 5 Inhibitors
8%
Phosphoinositide 3-kinase (PI3K)
8%
Potential Treatments
8%
Receptor Signaling
8%
Risk Factors
8%
Smooth muscle Dysfunction
8%
Specific Intent
8%
Structural Benefits
16%
Systemic Toxicity
8%
Therapeutic Angiogenesis
100%
Therapeutic Strategies
8%
Traumatic Injury
8%
Traumatic Vascular Injury
8%
Treatment Options
8%
United States
8%
Vascular Abnormalities
8%
Vascular Bed
8%
Vascular Endothelial Growth Factor
33%
Vascular Endothelial Growth Factor Receptor (VEGFR)
33%
Vascular Endothelial Growth Factor Signaling
8%
Vascular Endothelium
8%
Vascular Injury
41%
Vascular Smooth muscle Cell Function
8%
Vascular Smooth muscle Cells
16%
Vascular Structure
16%
Vulnerability
8%
Medicine and Dentistry
Angiogenesis
100%
Blood Vessel
16%
Blood Vessel Injury
50%
Cell Function
8%
Cell Interaction
8%
Corpus Cavernosum Penis
16%
Endothelial Cell
16%
Erectile Dysfunction
100%
Fibroblast Growth Factor 2
16%
Growth Factor
25%
Health Care
16%
Hypercholesterolemia
75%
Injury
16%
Mediator
16%
Nitric Oxide
16%
Pathophysiology
8%
Phosphodiesterase V Inhibitor
8%
Phosphoinositide 3-Kinase
8%
Receptor Mediated Signaling
8%
Smooth Muscle
8%
Vascular Endothelium
8%
Vascular Smooth Muscle
8%
Vascular Smooth Muscle Cell
16%
Vasculotropin
41%
Vasculotropin Receptor
25%